logo
  

CVS Pharmacy To Offer Pfizer-BioNTech's COVID-19 Pediatric Vaccine Starting On Sunday

CVS Health (CVS) said that certain CVS Pharmacy will offer a two-dose primary series of the Pfizer-BioNTech COVID-19 pediatric vaccine to children ages five to 11 years of age starting on Sunday.

It follows authorization of the vaccine by the Centers for Disease Control and Prevention (CDC) based on guidance from the organization's Advisory Committee on Immunization Practices and Food and Drug Administration (FDA) Emergency Use Authorization.

The vaccine will be available at nearly 1,700 CVS Pharmacy locations in 46 states, Puerto Rico and Washington D.C., the company said.

In a separate press release, Rite Aid said it is prepared to begin administering doses of Pfizer-BioNTech's COVID-19 pediatric vaccine to children aged 5-11 as soon as the 10 microgram doses are distributed to Rite Aid, which is expected at the end of this week.

The first available appointments for age 5-11 doses will be on Saturday, November 6. Those appointments may be booked through our scheduling tool beginning Thursday, November 4.

The Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age is administered as a two-dose primary series, 3 weeks apart, but is a lower dose (10 micrograms) than that used for individuals 12 years of age and older (30 micrograms).

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration or FDA has urged infant formula manufacturers to import infant formula products to the United States to meet the ongoing severe supply shortage. In order to further increase the availability of infant formula in the country, while protecting the health of infants, the regulator announced a guidance outlining increased flexibilities for the global manufacturers Retail giant Walmart Inc. reported Tuesday a profit for the first quarter of fiscal 2023 that declined 24.8 percent from last year, hurt by lower gross margins and net losses on equity investments. Adjusted earnings per share also missed analysts' expectations, but quarterly revenues topped it. The retailer also cut its earnings guidance for the second quarter and for the full-year 2023. Billionaire and Tesla CEO Elon Musk, who is in deal to acquire Twitter Inc., may seek a lower price for the social media platform as he estimates that there could be at least four times more fake accounts than what the company informed, Reuters reported. It was in late April that Twitter agreed to accept Musk's about $44 billion takeover offer and to become a privately held company.
Follow RTT